Can a second CAR T-Cell infusion beat lymphoma that returns?
NCT ID NCT04419909
First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time
Summary
This early-stage trial is testing whether a second infusion of a patient's own genetically modified immune cells (CAR T-cells) can safely treat B-cell lymphoma that has returned after an initial successful response. The study enrolls people with diffuse large B-cell or follicular lymphoma whose cancer came back at least six months after their first CAR T-cell treatment. The main goal is to check safety, with a secondary look at whether the cancer shrinks or disappears.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a second infusion of the patient's own genetically modified immune cells (CAR T-cells) targeting CD19
- What this could lead to
- If it works, this could offer a second chance at remission for people whose lymphoma returns after an initial CAR T-cell success.
- What could go wrong
- This is a very early, small Phase 1 safety trial, so it is unclear whether retreatment will be effective or safe. Side effects from CAR T-cells can be severe, including cytokine release syndrome and neurological problems.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could the key to better CAR-T therapy lie in the gut?
- Liver-Friendly lymphoma treatment? new drug dosing study offers hope
- New drug combo aims to tame aggressive lymphoma in frail patients
- New combo therapy aims to boost remission in Hard-to-Treat lymphoma
- Double-Pronged immune cells take aim at stubborn blood cancers
- Exosomes: the decoy receptors that may sabotage lymphoma treatment